the treatment of cerebrotendinous xanthomatosis
with the Prix Galien MedStartup
in New York
About us
Pipeline
Programs
Indication / target
Research
Poc
IND ENABLING
PHASE 1/2
PHASE 3
PARTNER
VTX-801
VTX-801 is an AAV-based gene therapy for Wilson’s disease. VTX-801 contains a corrective version of the ATP7B gene, which is malfunctioning in patients affected with Wilson’s disease, and is currently under clinical evaluation in a Phase 1/2 clinical safety and efficacy study (GATEWAY) with a 12-week readout. VTX-801 received US and EU Orphan Drug Designation (ODD), and fast track designation by FDA.
VTX-802
VTX-803
VTX-804
VTX-805
VTX-806
VTX-PSM
VTX-PID
VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy.
Our investors
Strong and Committed Investors
Vivet Therapeutics has investors from both sides of the ocean, bringing strong support, network and long-term commitment.
Building a unique company for unique treatments
Vivet is a strong team of experienced scientists and technical experts who are passionate about innovative science and dedicated to improving patients’ lives by curing genetic disorders. We have a unique pipeline of liver-directed AAV products, as well as solid technological platforms which allow us to unlock the full potential of gene therapy.
Science for new path
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
Developping Breakthrough Medecine
Through the unique design of the GATEWAY trial, we intent to demonstrate the effectiveness of our lead asset, VTX-801, to restore copper homeostasis in Wilson disease patients. The innovative use of a biomarker will allow for a quick readout of treatment response that will trigger standard of care treatment withdrawal.
Building a unique company for unique treatments
Vivet is a strong team of experienced scientists and technical experts who are passionate about innovative science and dedicated to improving patients’ lives by curing genetic disorders. We have a unique pipeline of liver-directed AAV products, as well as solid technological platforms which allow us to unlock the full potential of gene therapy.
Science for new path
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
Developping Breakthrough Medecine
Through the unique design of the GATEWAY trial, we intent to demonstrate the effectiveness of our lead asset, VTX-801, to restore copper homeostasis in Wilson disease patients. The innovative use of a biomarker will allow for a quick readout of treatment response that will trigger standard of care treatment withdrawal.
gene therapy
Program
years of cumulated
Experience
News
Rare Disease Day – February 29
To mark #RareDiseaseDay on 29 February, our CEO Jean-Philippe Combal, spoke to pharmaphorum
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy
PRESS RELEASE Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics (“Vivet”), a clinical- stage biotechnology company
Events
J.P.Morgan 2024 – Annual Healthcare Conference in San Francisco
Jean-Philippe Combal – CEO and Gloria Gonzalez – CSO, are going to San Francisco for #JPM24! Let’s make the most of this opportunity. Please send
Vivet spronsoring and attending the Spanish Wilson disease patients association annual conference in Valencia, Spain
The Vivet Therapeutics team had the honor of sponsoring and attending the Spanish Wilson’s Disease Association meeting in Valencia, Spain (learn more: https://lnkd.in/eUMB-AUw ) over the
AASLD – The Liver Meeting in Boston
Vivet Therapeutics is pleased to join AASLD – The Liver Meeting in Boston, MA this year. Meet with Vivet Therapeutics for an update on the
Contact Us
VIVET THERAPEUTICS
- 80 Boulevard Haussmann 75008 Paris, FRANCE
- Av. de Pío XII, 55 31008 Pamplona Spain
- info@vivet.digital-agency.fr
